BioGX Expands Xfree Respiratory PCR With COVID-19/Flu A/Flu B Multiplex, Group A Streptococcus, Mycoplasma Pneumoniae

BioGX, a global provider of molecular diagnostic solutions, announces the availability of three new Xfree™ Direct-Sample-to-Answer PCR multiplexes for the detection of Group A Streptococcus, Mycoplasma pneumoniae and Flu A, Flu B, COVID-19 N1/RdRp. Xfree Flu A, Flu B, COVID-19 and Group A Streptococcus were previously CE-IVD marked while Mycoplasma pneumoniae is available as research use only. Laboratories can request custom manufactured formats for high-throughput use that may be validated for their intended use on a variety of real-time PCR platforms including, the BioGX pixl™, Applied Biosystems 7500, ThermoFisher QuantStudio and Bio-Rad CFX Touch. 

"Our Xfree chemistry has proven to be highly robust in our FDA-EUA COVID-19 test. We are excited to offer expanded respiratory panels to  equip our customers with cost-effective, rapid PCR  workflows," said Shahin Iqbal, Ph.D., President & COO of BioGX.

Xfree technology provides a complete lyophilized test in a single tube in the trusted BioGX Sample-Ready format for extraction-free, direct sample addition real-time PCR testing. This format eliminates pre-treatment and nucleic acid extraction steps, enabling labs with a simple Sample-to-Answer workflow. The test can be shipped anywhere in the world without refrigeration.

To request more information on BioGX Xfree products and our other testing solutions, please contact sales@biogx.com.

Contact Information:
Bill Standwill
Head of Marketing
marketing@biogx.com
(205) 250-8055


Original Source: BioGX Expands Xfree Respiratory PCR With COVID-19/Flu A/Flu B Multiplex, Group A Streptococcus, Mycoplasma Pneumoniae
Previous articleNantucket Whaler Launches Fall-Winter 2023 Collection Inspired by Coastal Style
Next articleFortifeye Vitamins Introduces rTG Omgea 3 Fish Oil, a Revolutionary Leap Forward in Nutritional Health